The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 7
- 7 renewals
- Median first-year cost
- $999,578
- $6,797,391 in all
- Institutions
- 7
- 7 contact PIs
- Patents
- 1
- from 1 funded project
Awards by fiscal year
Fiscal years 2014 to 2026.
Most frequent institutions
- ADVENT THERAPEUTICS, INC.1
- ANNOVIANT, INC1
- DNA MEDICINE INSTITUTE1
- HILLHURST BIOPHARMACEUTICALS, INC.1
- POLYVASCULAR INC1
and 2 other institutions
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-O (O3))3
- Special Emphasis Panel (ZHL1 CSR-F (O1))2
- Special Emphasis Panel (ZHL1 CSR-F (O2))2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2025 | An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia2R44HL147734-04 | Jones, Curtis | RETHAM TECHNOLOGIES, INC., WI | First-year cost $1,154,002 | Study section ZHL1 |
| FY2025 | DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY2R44HL158304-04A1 | Tang, Beverly | STARLIGHT CARDIOVASCULAR, INC., CA | First-year cost $999,918 | Study section ZHL1 |
| FY2025 | Development of a Polymeric Percutaneous Pulmonary Valve for Use in Young Children2R44HL129577-04A1 | Harrington, Daniel AKhalil, Vivian Fikry | POLYVASCULAR INC, TX | First-year cost $815,391 | Study section ZHL1 |
| FY2024 | Hemophilia Point-of-Care Monitoring Device and App2R44HL151147-03 | Chan, Eugene Yan-Ho | DNA MEDICINE INSTITUTE, MA | First-year cost $999,888 | Study section ZHL1 |
| FY2024 | Pulmonary Valved Graft with Regeneration Potential for Pediatric Patients2R44HL147771-04 | Houde, Ajay | ANNOVIANT, INC, GA | First-year cost $833,493 | Study section ZHL1 |
| FY2023 | HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease2R44HL131065-05 | Gomperts, Edward | HILLHURST BIOPHARMACEUTICALS, INC., CA | First-year cost $999,578 | Study section ZHL1 |
| FY2023 | Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation2R44HL142353-04 | Gelfand, CraigRehan, Virender K | ADVENT THERAPEUTICS, INC., PA | First-year cost $995,121 | Study section ZHL1 |
Patents from its funded projects
1 patent names 1 of the 7 funded projects.
- US 12,366,584 (opens the patent at USPTO, a PDF, in a new tab)IDENTIFICATION OF PLATELET ACTIVATING ANTIBODIESGranted July 22, 2025 to RETHAM TECHNOLOGIES, INC.R44HL147734 · RETHAM TECHNOLOGIES, INC., WI
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.